XLO Key Statistics, Chart & Performance
The current stock price of XLO is 0.68 USD. In the past month the price decreased by -5.31%. In the past year, price decreased by -38.18%.
XLO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B |
Related stock screener links
About XLO
Company Profile
Xilio Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Waltham, Massachusetts and currently employs 64 full-time employees. The company went IPO on 2021-10-22. The firm is engaged in discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to build a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines, antibodies, bispecific and immune cell engagers. Its pipeline products include Vilastobart (XTX101), XTX301, XTX501, and tumor-activated bispecific molecules and immune cell-engaging molecules. XTX101 is an investigational tumor-activated, Fc-enhanced, high-affinity binding anti-CTLA-4 monoclonal antibody. XTX301, a tumor-activated, engineered interleukin 12, or IL-12, therapy.
Company Info
XILIO THERAPEUTICS INC
828 Winter Street, Suite 300
Waltham MASSACHUSETTS US
Employees: 64
Phone: 16174304680
XILIO THERAPEUTICS INC / XLO FAQ
What does XILIO THERAPEUTICS INC do?
Xilio Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Waltham, Massachusetts and currently employs 64 full-time employees. The company went IPO on 2021-10-22. The firm is engaged in discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to build a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines, antibodies, bispecific and immune cell engagers. Its pipeline products include Vilastobart (XTX101), XTX301, XTX501, and tumor-activated bispecific molecules and immune cell-engaging molecules. XTX101 is an investigational tumor-activated, Fc-enhanced, high-affinity binding anti-CTLA-4 monoclonal antibody. XTX301, a tumor-activated, engineered interleukin 12, or IL-12, therapy.
Can you provide the latest stock price for XILIO THERAPEUTICS INC?
The current stock price of XLO is 0.68 USD. The price decreased by -6.01% in the last trading session.
What is the dividend status of XILIO THERAPEUTICS INC?
XLO does not pay a dividend.
What is the ChartMill technical and fundamental rating of XLO stock?
XLO has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Where is XILIO THERAPEUTICS INC (XLO) stock traded?
XLO stock is listed on the Nasdaq exchange.
Can you provide the growth outlook for XILIO THERAPEUTICS INC?
The Revenue of XILIO THERAPEUTICS INC (XLO) is expected to grow by 492.79% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the employee count for XLO stock?
XILIO THERAPEUTICS INC (XLO) currently has 64 employees.
XLO Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to XLO. When comparing the yearly performance of all stocks, XLO is a bad performer in the overall market: 88.62% of all stocks are doing better.
XLO Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to XLO. XLO has a bad profitability rating. Also its financial health evaluation is rather negative.
XLO Financial Highlights
Over the last trailing twelve months XLO reported a non-GAAP Earnings per Share(EPS) of -0.55. The EPS increased by 67.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -43.75% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
XLO Forecast & Estimates
5 analysts have analysed XLO and the average price target is 2.04 USD. This implies a price increase of 200% is expected in the next year compared to the current price of 0.68.
For the next year, analysts expect an EPS growth of 64.16% and a revenue growth 492.79% for XLO